Company intelligence / Profile preview

Shape Therapeutics

Seattle, Washington, United Statesshapetx.com ↗

Ownership: Private
Employees: ~200
Development stage: Preclinical

Overview

Shape Therapeutics has demonstrated preclinical proof-of-concept for its programmable RNA medicine platforms. The company leverages AI-driven design to develop novel RNA therapeutics and next-generation viral vectors. No human clinical trial results have been published as of May 2025.

Therapeutic areas: OphthalmologyRare DiseasesNeurologyMetabolic Disorders
Modalities: Programmable RNA medicines (RNA editing)Adeno-associated virus (AAV) gene therapies
Industry: Biotech

Drug pipeline

2 assets

RNAfix

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Roche (collaboration on next-gen tissue-specific AAV gene therapies)Otsuka Pharmaceuticals (ophthalmology portfolio expansion with ocular gene therapies)

Beyond the preview

Go deeper on Shape Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shape Therapeutics.

Explore the full profile